Tenet

Tenet Medicines is a privately-held biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases. Tenet’s lead asset, TNT119, also known as budoprutug, is an anti-CD19 targeted monoclonal antibody designed to deplete B cells. TNT119 has a clinically validated mechanism of action and is being advanced for indications with high unmet needs, including systemic lupus erythematosus (SLE), immune thrombocytopenia (ITP), and membranous nephropathy (MN). Tenet Medicines was founded in 2023 and is headquartered in Scotch Plains, New Jersey.